Updated OGE Senior Executive Service Performance Review Board, 53250-53251 [E8-21447]
Download as PDF
53250
Federal Register / Vol. 73, No. 179 / Monday, September 15, 2008 / Notices
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than
September 29, 2008.
A. Federal Reserve Bank of Atlanta
(Steve Foley, Vice President) 1000
Peachtree Street, N.E., Atlanta, Georgia
30309:
1. Leslie D. Ligon, Jr., Clinton,
Louisiana; to acquire additional shares
of Clinton Bancshares, Inc., and thereby
acquire shares of Landmark Bank, both
of Clinton, Louisiana.
Board of Governors of the Federal Reserve
System, September 10, 2008.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E8–21451 Filed 9–12–08; 8:45 am]
FEDERAL RESERVE SYSTEM
mstockstill on PROD1PC66 with NOTICES
Notice of Proposals to Engage in
Permissible Nonbanking Activities or
to Acquire Companies that are
Engaged in Permissible Nonbanking
Activities
The companies listed in this notice
have given notice under section 4 of the
Bank Holding Company Act (12 U.S.C.
1843) (BHC Act) and Regulation Y (12
CFR Part 225) to engage de novo, or to
acquire or control voting securities or
assets of a company, including the
companies listed below, that engages
either directly or through a subsidiary or
other company, in a nonbanking activity
that is listed in § 225.28 of Regulation Y
(12 CFR 225.28) or that the Board has
determined by Order to be closely
related to banking and permissible for
bank holding companies. Unless
otherwise noted, these activities will be
conducted throughout the United States.
Each notice is available for inspection
at the Federal Reserve Bank indicated.
The notice also will be available for
inspection at the offices of the Board of
Governors. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act. Additional information on all
bank holding companies may be
obtained from the National Information
Center website at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding the applications must be
received at the Reserve Bank indicated
or the offices of the Board of Governors
not later than October 10, 2008.
A. Federal Reserve Bank of Chicago
(Burl Thornton, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690-1414:
20:22 Sep 12, 2008
Board of Governors of the Federal Reserve
System, September 10, 2008.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E8–21452 Filed 9–12–08; 8:45 am]
BILLING CODE 6210–01–S
GENERAL SERVICES
ADMINISTRATION
Committee Act (FACA) (Pub. L. 92–
463). The purpose of this subcommittee
is to advise GSA in issues pertaining to
Service Disabled Veteran Owned Small
Businesses (SDVOSB’s) as outlined in
Gun number 2 (Advocacy) of GSA’s 21
Gun Salute initiative for SDVOSB’s.
Information on the 21 Gun Salute can be
found at https://www.gsa.gov/servicedisabled. Please note that nominees who
are selected and agree to serve may be
asked to complete a financial disclosure
form.
Dated: September 9, 2008.
Michael Rigas,
Deputy Associate Administrator, Office of
Small Business Utilization, General Services
Administration.
[FR Doc. E8–21455 Filed 9–12–08; 8:45 am]
Office of Small Business Utilization;
Small Business Advisory Committee;
BILLING CODE 6210–01–S
VerDate Aug<31>2005
1. PrivateBancorp, Inc., Chicago,
Illinois; to acquire 100 percent of the
voting shares of The PrivateWealth
Trust Company, a federal savings bank
(in organization), Chicago, Illinois, and
thereby engage in operating a savings
bank pursuant to section 225.28(b)(4)(ii)
of Regulation Y.
Jkt 214001
BILLING CODE 6820–34–S
Notice of Request for Nominations for
Subcommittee on Service Disabled
Veteran Owned Small Business
(SDVOSB), GSA Small Business
Advisory Committee
OFFICE OF GOVERNMENT ETHICS
Office of Small Business
Utilization, GSA.
ACTION: Notice.
(OGE).
AGENCY:
The General Services
Administration (GSA) is requesting the
public to submit nominations of
individuals for the Service Disabled
Veteran Owned Small Business
Subcommittee of the GSA Small
Business Advisory Committee as a part
of GSA’s initiative to meet and exceed
its three percent contracting goal for
Service-Disabled Veteran-Owned Small
Businesses.
DATES: Interested parties should submit
the nomination form on or before
September 30, 2008.
ADDRESSES: The nomination form is
available at https://www.gsa.gov/servicedisabled and should be submitted to
sbac@gsa.gov. When submitting a
nomination via email, please put
‘‘SDVOSB Subcommittee nomination’’
in the subject line. Nominations may
also be sent by mail to: General Services
Administration, Small Business
Advisory Committee, 1800 F Street NW,
Room 6029, Washington, DC 20405.
Those wishing to send the
nominations by fax may do so using
(202) 501–2590.
SUMMARY:
FOR FURTHER INFORMATION CONTACT
Aaron Collmann, Room 6029, GSA
Building, 1800 F Street, NW.,
Washington, DC 20405 (202) 501–1021
or email at sbac@gsa.gov.
SUPPLEMENTARY INFORMATION: This
notice is published in accordance with
the provisions of the Federal Advisory
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
Updated OGE Senior Executive Service
Performance Review Board
AGENCY:
ACTION:
Office of Government Ethics
Notice.
SUMMARY: Notice is hereby given of the
appointment of the members of the
updated OGE Senior Executive Service
(SES) Performance Review Board.
DATES: Effective Date: September 15,
2008.
FOR FURTHER INFORMATION CONTACT:
Joseph E. Gangloff, Deputy Director for
Agency Programs, Office of Government
Ethics, Suite 500, 1201 New York
Avenue, NW., Washington, DC 20005–
3917; Telephone: 202–482–9300; TDD:
202–482–9293; FAX: 202–482–9238.
SUPPLEMENTARY INFORMATION: 5 U.S.C.
4314(c) requires each agency to
establish, in accordance with
regulations prescribed by the Office of
Personnel Management at 5 CFR part
430, subpart C and § 430.310 thereof in
particular, one or more Senior Executive
Service performance review boards. As
a small executive branch agency, OGE
has just one board. In order to ensure an
adequate level of staffing and to avoid
a constant series of recusals, the
designated members of OGE’s SES
Performance Review Board are being
drawn, as in the past, in large measure
from the ranks of other agencies. The
board shall review and evaluate the
initial appraisal of each OGE senior
executive’s performance by his or her
supervisor, along with any
recommendations in each instance to
the appointing authority relative to the
performance of the senior executive.
This notice updates the membership of
E:\FR\FM\15SEN1.SGM
15SEN1
Federal Register / Vol. 73, No. 179 / Monday, September 15, 2008 / Notices
OGE’s SES Performance Review Board
as it was most recently published at 72
FR 54666–54667 (September 26, 2007).
Approved: September 9, 2008.
Robert I. Cusick,
Director, Office of Government Ethics.
The following officials have been
appointed as regular members of the
SES Performance Review Board of the
Office of Government Ethics:
Joseph E. Gangloff [Chair], Deputy
Director for Agency Programs, Office
of Government Ethics;
Don W. Fox [Alternate Chair], General
Counsel, Office of Government Ethics;
Daniel L. Koffsky, Special Counsel,
Office of Legal Counsel, Department
of Justice;
David Maggi, Chief, Ethics Law and
Programs Division, Office of the
Assistant General Counsel for
Administration, Department of
Commerce; and
Robert A. Shapiro, Associate Solicitor
for Legal Counsel, Department of
Labor.
[FR Doc. E8–21447 Filed 9–12–08; 8:45 am]
BILLING CODE 6345–02–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2007–D–0434] (formerly
Docket No. 2007D–0386)
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Guidance for
Industry on Postmarketing Adverse
Event Reporting for Nonprescription
Human Drug Products Marketed
Without an Approved Application
AGENCY:
Food and Drug Administration,
HHS.
mstockstill on PROD1PC66 with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by October 15,
2008.
ADDRESSES: To ensure that comments on
the information collection are received,
VerDate Aug<31>2005
20:22 Sep 12, 2008
Jkt 214001
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
baguilar@omb.eop.gov. All comments
should be identified with the OMB
control number 0910–NEW and title
‘‘Guidance for Industry on
Postmarketing Adverse Event Reporting
for Nonprescription Human Drug
Products Marketed Without an
Approved Application.’’ Also include
the FDA docket number found in
brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Berbakos, Office of
Information Management (HFA–710),
Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857,
301–796–3792.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Guidance for Industry on
Postmarketing Adverse Event Reporting
for Nonprescription Human Drug
Products Marketed Without an
Approved Application
Public Law 109–462, the Dietary
Supplement and Nonprescription Drug
Consumer Protection Act, amended the
Federal Food, Drug, and Cosmetic Act
(the act) to add safety reporting
requirements for nonprescription drug
products that are marketed without an
approved application. In accordance
with section 760(b) of the act (21 U.S.C.
379aa), the manufacturer, packer, or
distributor whose name appears on the
label of a nonprescription drug
marketed in the United States without
an approved application (referred to as
the responsible person) must submit to
FDA any report of a serious adverse
event associated with such drug when
used in the United States, accompanied
by a copy of the label on or within the
retail package of such drug. In addition,
the responsible person must submit
followup reports of new medical
information related to a submitted
serious adverse event report that is
received within 1 year of the initial
report (section 760(c)(2) of the act).
Section 760(e) of the act also requires
that responsible persons maintain
records of nonprescription drug adverse
event reports, whether or not the event
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
53251
is serious, for a period of 6 years. The
guidance document provides
information on: (1) The minimum data
elements that should be included in a
serious adverse event report, (2) the
label that should be included with the
report, (3) reporting formats for paper
and electronic submissions, and (4) how
and where to submit the reports.
Title: Guidance for Industry on
Postmarketing Adverse Event Reporting
for Nonprescription Human Drug
Products Marketed Without an
Approved Application.
Description of Respondents:
Respondents to this collection of
information are manufacturers, packers,
or distributors whose name appears on
the label of a nonprescription drug
marketed in the United States without
an approved application.
Burden Estimate: FDA is requesting
public comment on estimates of the
number of annual submissions from
these respondents and recordkeeping, as
required by Public Law 109–462 and
described in the guidance
‘‘Postmarketing Adverse Event
Reporting for Nonprescription Human
Drug Products Marketed Without an
Approved Application.’’ The estimates
for annual reporting and recordkeeping
are based on FDA’s knowledge of
adverse drug experience reports
historically submitted annually for
prescription drug products and for
nonprescription drug products marketed
under an approved application,
including knowledge about the time
needed to prepare the reports and to
maintain records.
FDA receives approximately 2,500
serious adverse event reports for
nonprescription drug products marketed
under approved applications, which
comprise approximately 20 percent of
the overall nonprescription drug market.
Based on this data, we estimate between
10,000 and 15,000 (i.e., 12,500) total
annual responses from approximately
50 respondents for nonprescription
drugs marketed without an approved
application, and that each submission
will take approximately 2 hours to
prepare and submit to FDA.
In the Federal Register of October 15,
2007 (72 FR 58316), FDA published a
60-day notice requesting public
comment on the information collection
provisions. No comments were received
on the information collection.
FDA estimates the burden of this
collection of information as follows:
E:\FR\FM\15SEN1.SGM
15SEN1
Agencies
[Federal Register Volume 73, Number 179 (Monday, September 15, 2008)]
[Notices]
[Pages 53250-53251]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-21447]
=======================================================================
-----------------------------------------------------------------------
OFFICE OF GOVERNMENT ETHICS
Updated OGE Senior Executive Service Performance Review Board
AGENCY: Office of Government Ethics (OGE).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given of the appointment of the members of
the updated OGE Senior Executive Service (SES) Performance Review
Board.
DATES: Effective Date: September 15, 2008.
FOR FURTHER INFORMATION CONTACT: Joseph E. Gangloff, Deputy Director
for Agency Programs, Office of Government Ethics, Suite 500, 1201 New
York Avenue, NW., Washington, DC 20005-3917; Telephone: 202-482-9300;
TDD: 202-482-9293; FAX: 202-482-9238.
SUPPLEMENTARY INFORMATION: 5 U.S.C. 4314(c) requires each agency to
establish, in accordance with regulations prescribed by the Office of
Personnel Management at 5 CFR part 430, subpart C and Sec. 430.310
thereof in particular, one or more Senior Executive Service performance
review boards. As a small executive branch agency, OGE has just one
board. In order to ensure an adequate level of staffing and to avoid a
constant series of recusals, the designated members of OGE's SES
Performance Review Board are being drawn, as in the past, in large
measure from the ranks of other agencies. The board shall review and
evaluate the initial appraisal of each OGE senior executive's
performance by his or her supervisor, along with any recommendations in
each instance to the appointing authority relative to the performance
of the senior executive. This notice updates the membership of
[[Page 53251]]
OGE's SES Performance Review Board as it was most recently published at
72 FR 54666-54667 (September 26, 2007).
Approved: September 9, 2008.
Robert I. Cusick,
Director, Office of Government Ethics.
The following officials have been appointed as regular members of
the SES Performance Review Board of the Office of Government Ethics:
Joseph E. Gangloff [Chair], Deputy Director for Agency Programs, Office
of Government Ethics;
Don W. Fox [Alternate Chair], General Counsel, Office of Government
Ethics;
Daniel L. Koffsky, Special Counsel, Office of Legal Counsel, Department
of Justice;
David Maggi, Chief, Ethics Law and Programs Division, Office of the
Assistant General Counsel for Administration, Department of Commerce;
and
Robert A. Shapiro, Associate Solicitor for Legal Counsel, Department of
Labor.
[FR Doc. E8-21447 Filed 9-12-08; 8:45 am]
BILLING CODE 6345-02-P